MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 05:13:16 20/06/2024 pm IST | ||
| 18.57 EUR / 18.58 EUR | +1.23% |
|
| Current month | +8.64% | ||
| 1 month | +12.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 18.48 | +0.71% |
| 19/24/19 | 18.35 | +0.38% |
| 18/24/18 | 18.28 | -0.92% |
| 17/24/17 | 18.45 | -1.81% |
| 14/24/14 | 18.79 | +1.40% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 12:25 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA83D1 |
| ISIN | DE000MA83D19 |
| Date issued | 20/07/2021 |
| Strike | 294.7 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.79 € |
|---|---|
| Lowest since issue | 0.33 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984.2
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.07%
- Stock Market
- Certificates
- Certificat
